
WHAT IS CLAIMED IS:

1. Use of a nitroxyl donating compound, or a pharmaceutical composition comprising the nitroxyl donating compound and at least one pharmaceutically acceptable excipient in the manufacture of a medicament for the treatment of a cardiovascular disease responsive to nitroxyl therapy, wherein the nitroxyl donating compound is a compound of formula (1):




(1),

wherein the nitroxyl donating compound, or the pharmaceutical composition comprising the nitroxyl donating compound and at least one pharmaceutically acceptable excipient is to be administered intravenously to a patient having said cardiovascular disease in an amount of about 6 µg/kg/min of nitroxyl donating compound for about 4 hours, and

wherein the nitroxyl donating compound, or the pharmaceutical composition comprising the nitroxyl donating compound and at least one pharmaceutically acceptable excipient is to be administered intravenously to the patient in an amount of about 12 µg/kg/min of nitroxyl donating compound for about 44 hours.

2. Use of a nitroxyl donating compound, or a pharmaceutical composition comprising the nitroxyl donating compound and at least one pharmaceutically acceptable excipient in the manufacture of a medicament for the treatment of a cardiovascular disease responsive to nitroxyl therapy, wherein the nitroxyl donating compound is a compound of formula (1):



(1),

wherein the nitroxyl donating compound, or a pharmaceutical composition comprising the nitroxyl donating compound and at least one pharmaceutically acceptable excipient is to be administered intravenously to a patient having said cardiovascular disease in an amount of about 3 µg/kg/min of nitroxyl donating compound for about 4 hours,

wherein the nitroxyl donating compound, or the pharmaceutical composition comprising the nitroxyl donating compound and at least one pharmaceutically acceptable excipient is to be administered intravenously to the patient in an amount of about 6 µg/kg/min of nitroxyl donating compound for about 4 hours, and

wherein the nitroxyl donating compound, or the pharmaceutical composition comprising the nitroxyl donating compound and at least one pharmaceutically acceptable excipient is to be administered intravenously to the patient in an amount of about 12 µg/kg/min of nitroxyl donating compound for about 40 hours.

3. The use of claim 1 or 2, wherein the cardiovascular disease is heart failure.

4. The use of claim 3, wherein the cardiovascular disease is acute decompensated heart failure.

5. The use of any one of claims 1 to 4, wherein the composition is formulated at a pH of from 5 to 6.

6. The use of any one of claims 1 to 4, wherein the composition is formulated at a pH of from 5.5 to 6.2.

7. The use of any one of claims 1 to 4, wherein the composition is formulated at a pH of about 6.

8. The use of any one of claims 1 to 7, wherein the at least one pharmaceutically acceptable excipient is a buffering agent.

9. The use of claim 8, wherein the buffering agent is potassium acetate.

10. The use of claim 8, wherein the buffering agent is potassium phosphate.

11. The use of any one of claims 1 to 10, further comprising a stabilizing agent.

12. The use of claim 11, wherein the stabilizing agent is a cyclodextrin.

13. The use of claim 12, wherein the cyclodextrin is a sulfo-*n*-butyl ether derivative of β-cyclodextrin having six or seven sulfo-*n*-butyl ether groups per cyclodextrin molecule.

14. The use of claim 12, wherein the cyclodextrin is a sulfo-*n*-butyl ether derivative of β-cyclodextrin, which is a β-cyclodextrin having at least one -OH group that is derivatized by replacing the hydrogen atom thereof with $–(CH_2)_4\text{-}S(O)_2\text{-}O^-Z^+$, wherein each Z is a Na^+.

15. The use of claim 12, wherein the molar ratio between the nitroxyl donating compound and the cyclodextrin present in the composition is from 0.02:1 to 2:1.

16. The use of claim 12, wherein the molar ratio between the nitroxyl donating compound and the cyclodextrin present in the composition is from 0.05:1 to 1.5:1.

17. The use of claim 12, wherein the molar ratio between the nitroxyl donating compound and the cyclodextrin present in the composition is from 0.5:1 to 1:1.

18. The use of any one of claims 1 to 4, wherein the at least one pharmaceutically acceptable excipient is a cyclodextrin.

19. The use of claim 18, wherein the cyclodextrin is a sulfo-*n*-butyl ether derivative of β-cyclodextrin having six or seven sulfo-*n*-butyl ether groups per cyclodextrin molecule.

20. The use of claim 18, wherein the cyclodextrin is a sulfo-*n*-butyl ether derivative of β-cyclodextrin, which is a β-cyclodextrin having at least one -OH group that is derivatized by replacing the hydrogen atom thereof with $–(CH_2)_4\text{-}S(O)_2\text{-}O^-Z^+$, wherein each Z is a Na^+.

21. The use of claim 18, wherein the molar ratio between the nitroxyl donating compound and the cyclodextrin present in the composition is from 0.02:1 to 2:1.

22. The use of claim 18, wherein the molar ratio between the nitroxyl donating compound and the cyclodextrin present in the composition is from 0.05:1 to 1.5:1.

23. The use of claim 18, wherein the molar ratio between the nitroxyl donating compound and the cyclodextrin present in the composition is from 0.5:1 to 1:1.